BRIEF-Spain's Iberdrola sees profits growing "mid single digit" in 2017
* Says sees Ebitda, net profit growing "mid single digit" in 2017 Further company coverage: (Madrid Newsroom)
April 30 WellPoint Inc said on Wednesday during a conference call that it had spent $50 million on hepatitis C drugs during the first quarter.
That was the total amount the company spent in 2013 on treatments, it said. Gilead Sciences introduced Sovaldi this year, and with its $84,000 price tag and high cure rates, it has been closely watched by insurers tracking expenses.
WellPoint added $100 million in additional hepatitis C drug costs to its 2014 outlook and said it continued to watch its use closely. (Reporting by Caroline Humer; Editing by Lisa Von Ahn)
* Applied to United Kingdom Listing Authority to cancel standard listing of company's common stock
* Aims for mid 1-digit pct gain in 2017 adj group EBITDA (Releads on guidance for crop science division)